CSI Market
Sign In | Register

Pyxis Oncology Inc (PYXS) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access PYXS Annual Cash Flow →
Examining cash flow movements between Pyxis Oncology Inc and Jun 30 2025 reveals how Jun 30 2026 allocates cash as operating conditions evolve.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-48.62
Depreciation & amortization0.76
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
Research and Development in Process0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation6.74
Income (Loss) from Equity Method Investments0.00
Increase (Decrease) in Derivative Liabilities0.00
Operating Lease Expense0.23
Non Cash Gain Loss From Equity Method Investment In Joint Venture-
Increase Decrease In Operating Lease Liability-0.40
Income taxes0.00
Unrealized Gain (Loss) on Derivatives0.00
Increase (Decrease) in Accounts Receivable0.00
Increase (Decrease) in Accounts Payable-7.62
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities3.83
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-1.51
Other Working Capital0.02
Other Noncash Income (Expense)0.00
Other net0.43
Payments for (Proceeds from) Other Operating Activities1.76
Discontinued operations0.00
Net Cash flow from Operating Activities-44.21
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Payments to Acquire Available-for-sale Securities, Debt-13.99
Real Estate Investments0.00
Redemption Of Marketable Debt Securities27.36
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Cash Acquired from Acquisition0.00
Payments to Acquire Interest in Joint Venture0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net51.66
Discontinued operations0.00
Net Cash Flow from Investing Activities37.67
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock10.05
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net-0.08
Other net0.00
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations16.89
Deferred Offering Costs In Accounts Payable And Accrued Expenses-
Right Of Use Asset Obtained In Exchange For Operating Lease Liability-
Proceeds From Stock Issued Under Atm Net-
Proceeds From Sale Of Stock Under Employee Stock Purchase Plan-
Proceeds From Issuance Of Common Stock Under Espp-
Right Of Use Asset Obtained In Exchange For Finance Lease Liability-
Shares Warrants And Replacement Stock Options And Restricted Stock Units Isued For Acquisition-
Capital Expenditures Incurred But Not Yet Paid-
Proceeds From Issuance Of Common Stock And Pre Funded Warrants In Private Placement-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities9.97
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-44.21
Total Cash Flow3.43
4 historic quarters locked

Sign in to unlock the full Pyxis Oncology Inc cash flow history.

Sign In Create Free Account

About Pyxis Oncology Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-347913

Figures are derived from filed reports and may be restated. Historical data is subject to revision.